Core Insights - Sana Biotechnology, Inc. has appointed Brian Piper as Executive Vice President and Chief Financial Officer, bringing over 25 years of biopharmaceutical financial and operational expertise [1][2] - The company anticipates generating initial clinical data for its therapies SC451 and SG293 within the next 12-18 months, which are aimed at treating type 1 diabetes and B-cell related diseases, respectively [2] - The leadership of Mr. Piper is expected to be critical in advancing the company's portfolio and optimizing long-term value creation [2][3] Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines, with a vision to repair and control genes and replace missing or damaged cells [4] - The company operates in Seattle, WA, Cambridge, MA, and South San Francisco, CA [4]